Circular RNA CDR1as Exerts Oncogenic Properties Partially through Regulating MicroRNA 641 in Cholangiocarcinoma

REFERENCES

• Rizvi S, Gores GJ. 2013. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145:1215–1229. https://doi.org/10.1053/j.gastro.2013.10.013.
   PubMed Web of Science ®Google Scholar
• Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. 2005. Cholangiocarcinoma. Lancet 366:1303–1314. https://doi.org/10.1016/S0140-6736(05)67530-7.
   PubMed Web of Science ®Google Scholar
• Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, Youssef BM, Klimstra D, Blumgart LH. 2001. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234:507–517. https://doi.org/10.1097/00000658-200110000-00010.
   PubMed Web of Science ®Google Scholar
• Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, Gores GJ. 2014. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60:1268–1289. https://doi.org/10.1016/j.jhep.2014.01.021.
   PubMed Web of Science ®Google Scholar
• de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Clary BM, Aldrighetti L, Ferrone CR, Zhu AX, Bauer TW, Walters DM, Gamblin TC, Nguyen KT, Turley R, Popescu I, Hubert C, Meyer S, Schulick RD, Choti MA, Gigot JF, Mentha G, Pawlik TM. 2011. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 29:3140–3145. https://doi.org/10.1200/JCO.2011.35.6519.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang J, Khanabdali R, Kalionis B, Tai X, Xia S. 2017. Circular RNAs: isolation, characterization and their potential role in diseases. RNA Biol 14:1715–1721. https://doi.org/10.1080/15476286.2017.1367886.
   PubMed Web of Science ®Google Scholar
• He J, Xie Q, Xu H, Li J, Li Y. 2017. Circular RNAs and cancer. Cancer Lett 396:138–144. https://doi.org/10.1016/j.canlet.2017.03.027.
   PubMed Web of Science ®Google Scholar
• Meng S, Zhou H, Feng Z, Xu Z, Tang Y, Li P, Wu M. 2017. CircRNA: functions and properties of a novel potential biomarker for cancer. Mol Cancer 16:94. https://doi.org/10.1186/s12943-017-0663-2.
   PubMed Web of Science ®Google Scholar
• Lasda E, Parker R. 2014. Circular RNAs: diversity of form and function. RNA 20:1829–1842. https://doi.org/10.1261/rna.047126.114.
   PubMed Web of Science ®Google Scholar
• Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, Evantal N, Memczak S, Rajewsky N, Kadener S. 2014. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell 56:55–66. https://doi.org/10.1016/j.molcel.2014.08.019.
   PubMed Web of Science ®Google Scholar
• Xia W, Qiu M, Chen R, Wang S, Leng X, Wang J, Xu Y, Hu J, Dong G, Xu PL, Yin R. 2016. Circular RNA has_circ_0067934 is upregulated in esophageal squamous cell carcinoma and promoted proliferation. Sci Rep 6:35576. https://doi.org/10.1038/srep35576.
   PubMed Web of Science ®Google Scholar
• Li P, Chen H, Chen S, Mo X, Li T, Xiao B, Yu R, Guo J. 2017. Circular RNA 0000096 affects cell growth and migration in gastric cancer. Br J Cancer 116:626–633. https://doi.org/10.1038/bjc.2016.451.
   PubMed Web of Science ®Google Scholar
• Wang Y, Mo Y, Gong Z, Yang X, Yang M, Zhang S, Xiong F, Xiang B, Zhou M, Liao Q, Zhang W, Li X, Li X, Li Y, Li G, Zeng Z, Xiong W. 2017. Circular RNAs in human cancer. Mol Cancer 16:25. https://doi.org/10.1186/s12943-017-0598-7.
   PubMed Web of Science ®Google Scholar
• Yu L, Gong X, Sun L, Zhou Q, Lu B, Zhu L. 2016. The circular RNA Cdr1as act as an oncogene in hepatocellular carcinoma through targeting miR-7 expression. PLoS One 11:e0158347. https://doi.org/10.1371/journal.pone.0158347.
   PubMed Web of Science ®Google Scholar
• Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, Loewer A, Ziebold U, Landthaler M, Kocks C, le Noble F, Rajewsky N. 2013. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495:333–338. https://doi.org/10.1038/nature11928.
   PubMed Web of Science ®Google Scholar
• Peng L, Yuan XQ, Li GC. 2015. The emerging landscape of circular RNA ciRS-7 in cancer. Oncol Rep 33:2669–2674. https://doi.org/10.3892/or.2015.3904.
   PubMed Web of Science ®Google Scholar
• Yang X, Xiong Q, Wu Y, Li S, Ge F. 2017. Quantitative proteomics reveals the regulatory networks of circular RNA CDR1as in hepatocellular carcinoma cells. J Proteome Res 16:3891–3902. https://doi.org/10.1021/acs.jproteome.7b00519.
   PubMed Web of Science ®Google Scholar
• Xu L, Zhang M, Zheng X, Yi P, Lan C, Xu M. 2017. The circular RNA ciRS-7 (Cdr1as) acts as a risk factor of hepatic microvascular invasion in hepatocellular carcinoma. J Cancer Res Clin Oncol 143:17–27. https://doi.org/10.1007/s00432-016-2256-7.
   PubMed Web of Science ®Google Scholar
• Weng W, Wei Q, Toden S, Yoshida K, Nagasaka T, Fujiwara T, Cai S, Qin H, Ma Y, Goel A. 2017. Circular RNA ciRS-7—a promising prognostic biomarker and a potential therapeutic target in colorectal cancer. Clin Cancer Res 23:3918–3928. https://doi.org/10.1158/1078-0432.CCR-16-2541.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yang D, Wei Y. 2018. Overexpressed CDR1as functions as an oncogene to promote the tumor progression via miR-7 in non-small-cell lung cancer. Onco Targets Ther 11:3979–3987. https://doi.org/10.2147/OTT.S158316.
   PubMed Web of Science ®Google Scholar
• Liu L, Liu F-B, Huang M, Xie K, Xie Q-S, Liu C-H, Shen M-J, Huang Q. 2019. Circular RNA ciRS-7 promotes the proliferation and metastasis of pancreatic cancer by regulating miR-7-mediated EGFR/STAT3 signaling pathway. Hepatobiliary Pancreat Dis Int 18:580–586. https://doi.org/10.1016/j.hbpd.2019.03.003.
   PubMed Web of Science ®Google Scholar
• Jiang X-M, Li Z-L, Li J-L, Xu Y, Leng K-M, Cui Y-F, Sun D-J. 2018. A novel prognostic biomarker for cholangiocarcinoma: circRNA Cdr1as. Eur Rev Med Pharmacol Sci 22:365–371. https://doi.org/10.26355/eurrev_201801_14182.
   PubMed Web of Science ®Google Scholar
• Yao R, Zheng H, Wu L, Cai P. 2018. miRNA-641 inhibits the proliferation, migration, and invasion and induces apoptosis of cervical cancer cells by directly targeting ZEB1. Onco Targets Ther 11:8965–8976. https://doi.org/10.2147/OTT.S190303.
   PubMed Web of Science ®Google Scholar
• Wang L-W, Li X-B, Liu Z, Zhao L-H, Wang Y, Yue L. 2019. Long non-coding RNA OIP5-AS1 promotes proliferation of gastric cancer cells by targeting miR-641. Eur Rev Med Pharmacol Sci 23:10776–10784. https://doi.org/10.26355/eurrev_201912_19780.
   PubMed Web of Science ®Google Scholar
• Fan Y-F, Yu Z-P, Cui X-Y. 2019. lncRNA colorectal neoplasia differentially expressed (CRNDE) promotes proliferation and inhibits apoptosis in non-small cell lung cancer cells by regulating the miR-641/CDK6 axis. Med Sci Monit 25:2745–2755. https://doi.org/10.12659/MSM.913420.
   PubMed Web of Science ®Google Scholar
• Hinske LC, Heyn J, Hubner M, Rink J, Hirschberger S, Kreth S. 2017. Intronic miRNA-641 controls its host gene’s pathway PI3K/AKT and this relationship is dysfunctional in glioblastoma multiforme. Biochem Biophys Res Commun 489:477–483. https://doi.org/10.1016/j.bbrc.2017.05.175.
   PubMed Web of Science ®Google Scholar
• Ewald F, Norz D, Grottke A, Hofmann BT, Nashan B, Jucker M. 2014. Dual inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. Invest New Drugs 32:1144–1154. https://doi.org/10.1007/s10637-014-0149-7.
   PubMed Web of Science ®Google Scholar
• Shen H, Zhang J, Zhang Y, Feng Q, Wang H, Li G, Jiang W, Li X. 2019. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway. Gene 698:50–60. https://doi.org/10.1016/j.gene.2019.02.044.
   PubMed Web of Science ®Google Scholar
• Tang W, Ji M, He G, Yang L, Niu Z, Jian M, Wei Y, Ren L, Xu J. 2017. Silencing CDR1as inhibits colorectal cancer progression through regulating microRNA-7. Onco Targets Ther 10:2045–2056. https://doi.org/10.2147/OTT.S131597.
   PubMed Web of Science ®Google Scholar
• Huang H, Wei L, Qin T, Yang N, Li Z, Xu Z. 2019. Circular RNA ciRS-7 triggers the migration and invasion of esophageal squamous cell carcinoma via miR-7/KLF4 and NF-kappaB signals. Cancer Biol Ther 20:73–80. https://doi.org/10.1080/15384047.2018.1507254.
   PubMed Web of Science ®Google Scholar
• Yan B, Zhang W, Mao X-W, Jiang L-Y. 2018. Circular RNA ciRS-7 correlates with advance disease and poor prognosis, and its down-regulation inhibits cells proliferation while induces cells apoptosis in non-small cell lung cancer. Eur Rev Med Pharmacol Sci 22:8712–8721. https://doi.org/10.26355/eurrev_201812_16636.
   PubMed Web of Science ®Google Scholar
• Sang M, Meng L, Sang Y, Liu S, Ding P, Ju Y, Liu F, Gu L, Lian Y, Li J, Wu Y, Zhang X, Shan B. 2018. Circular RNA ciRS-7 accelerates ESCC progression through acting as a miR-876-5p sponge to enhance MAGE-A family expression. Cancer Lett 426:37–46. https://doi.org/10.1016/j.canlet.2018.03.049.
   PubMed Web of Science ®Google Scholar
• Chen H, Mao M, Jiang J, Zhu D, Li P. 2019. Circular RNA CDR1as acts as a sponge of miR-135b-5p to suppress ovarian cancer progression. Onco Targets Ther 12:3869–3879. https://doi.org/10.2147/OTT.S207938.
   PubMed Web of Science ®Google Scholar
• Kong Q, Shu N, Li J, Xu N. 2018. miR-641 functions as a tumor suppressor by targeting MDM2 in human lung cancer. Oncol Res 26:735–741. https://doi.org/10.3727/096504017X15021536183490.
   PubMed Web of Science ®Google Scholar
• Chen J, Cui J, Guo X, Cao X, Li Q. 2018. Increased expression of miR-641 contributes to erlotinib resistance in non-small-cell lung cancer cells by targeting NF1. Cancer Med 7:1394–1403. https://doi.org/10.1002/cam4.1326.
   PubMed Web of Science ®Google Scholar
• Zhang N, Meng X, Mei L, Zhao C, Chen W. 2019. LncRNA DLX6-AS1 promotes tumor proliferation and metastasis in osteosarcoma through modulating miR-641/HOXA9 signaling pathway. J Cell Biochem 120:11478–11489. https://doi.org/10.1002/jcb.28426.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu B, Zhang P, Zhang J, Wang L. 2019. LncRNA TUSC8 inhibits the invasion and migration of cervical cancer cells via miR-641/PTEN axis. Cell Biol Int 43:781–788. https://doi.org/10.1002/cbin.11152.
   PubMed Web of Science ®Google Scholar
• Sithanandam G, Fornwald LW, Fields J, Anderson LM. 2005. Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. Oncogene 24:1847–1859. https://doi.org/10.1038/sj.onc.1208381.
   PubMed Web of Science ®Google Scholar
• Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang BH. 2006. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal 18:2262–2271. https://doi.org/10.1016/j.cellsig.2006.05.019.
   PubMed Web of Science ®Google Scholar
• Virtakoivu R, Pellinen T, Rantala JK, Perala M, Ivaska J. 2012. Distinct roles of AKT isoforms in regulating beta1-integrin activity, migration, and invasion in prostate cancer. Mol Biol Cell 23:3357–3369. https://doi.org/10.1091/mbc.E12-03-0213.
   PubMed Web of Science ®Google Scholar
• Boufraqech M, Zhang L, Jain M, Patel D, Ellis R, Xiong Y, He M, Nilubol N, Merino MJ, Kebebew E. 2014. miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. Endocr Relat Cancer 21:517–531. https://doi.org/10.1530/ERC-14-0077.
   PubMed Web of Science ®Google Scholar
• Obasi TC, Braicu C, Iacob BC, Bodoki E, Jurj A, Raduly L, Oniga I, Berindan-Neagoe I, Oprean R. 2018. Securidaca-saponins are natural inhibitors of AKT, MCL-1, and BCL2L1 in cervical cancer cells. Cancer Manag Res 10:5709–5724. https://doi.org/10.2147/CMAR.S163328.
   PubMed Web of Science ®Google Scholar
• Li J, Liu X, Li C, Wang W. 2019. miR-224-5p inhibits proliferation, migration, and invasion by targeting PIK3R3/AKT3 in uveal melanoma. J Cell Biochem 120:12412–12421. https://doi.org/10.1002/jcb.28507.
   PubMed Web of Science ®Google Scholar
• Nagao T, Kurosu T, Umezawa Y, Nogami A, Oshikawa G, Tohda S, Yamamoto M, Miura O. 2014. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera. PLoS One 9:e84746. https://doi.org/10.1371/journal.pone.0084746.
   PubMed Web of Science ®Google Scholar
• Wei C, Liu Z, Li L, Zhang Y, Fang Z, Fan Y. 2018. The anticancer effect of Huaier extract in renal cancer 786-O cells. Pharmacology 102:316–323. https://doi.org/10.1159/000492935.
   PubMed Web of Science ®Google Scholar
• Ge Y, Xu K. 2016. Alpha-synuclein contributes to malignant progression of human meningioma via the Akt/mTOR pathway. Cancer Cell Int 16:86. https://doi.org/10.1186/s12935-016-0361-y.
   PubMed Web of Science ®Google Scholar
• Wu C-E, Chen M-H, Yeh C-N. 2019. mTOR inhibitors in advanced biliary tract cancers. Int J Mol Sci 20:500. https://doi.org/10.3390/ijms20030500.
   PubMed Web of Science ®Google Scholar
• Ghini F, Rubolino C, Climent M, Simeone I, Marzi MJ, Nicassio F. 2018. Endogenous transcripts control miRNA levels and activity in mammalian cells by target-directed miRNA degradation. Nat Commun 9:3119. https://doi.org/10.1038/s41467-018-05182-9.
   PubMed Web of Science ®Google Scholar
• de la Mata M, Gaidatzis D, Vitanescu M, Stadler MB, Wentzel C, Scheiffele P, Filipowicz W, Großhans H. 2015. Potent degradation of neuronal miRNAs induced by highly complementary targets. EMBO Rep 16:500–511. https://doi.org/10.15252/embr.201540078.
   PubMed Web of Science ®Google Scholar
• Sheu-Gruttadauria J, Pawlica P, Klum SM, Wang S, Yario TA, Schirle Oakdale NT, Steitz JA, MacRae IJ. 2019. Structural basis for target-directed microRNA degradation. Mol Cell 75:1243–1255.e7. https://doi.org/10.1016/j.molcel.2019.06.019.
   PubMed Web of Science ®Google Scholar
• Wadkins RM, Jares-Erijman EA, Klement R, Rüdiger A, Jovin TM. 1996. Actinomycin D binding to single-stranded DNA: sequence specificity and hemi-intercalation model from fluorescence and 1H NMR spectroscopy. J Mol Biol 262:53–68. https://doi.org/10.1006/jmbi.1996.0498.
   PubMed Web of Science ®Google Scholar
• Luo Y, Tian Z, Hua X, Huang M, Xu J, Li J, Huang H, Cohen M, Huang C. 2020. Isorhapontigenin (ISO) inhibits stem cell-like properties and invasion of bladder cancer cell by attenuating CD44 expression. Cell Mol Life Sci 77:351–363. https://doi.org/10.1007/s00018-019-03185-3.
   PubMed Web of Science ®Google Scholar
• Kuang D, Zhou J, Yu L, Zeng W, Xiao J, Zhu G, Zhang Z, Chen X. 2016. DDAH1-V3 transcript might act as miR-21 sponge to maintain balance of DDAH1-V1 in cultured HUVECs. Nitric Oxide 60:59–68. https://doi.org/10.1016/j.niox.2016.09.008.
   PubMed Web of Science ®Google Scholar
• National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
   Google Scholar